Compare MPV & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | MXCT |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 155.8M |
| IPO Year | N/A | 2021 |
| Metric | MPV | MXCT |
|---|---|---|
| Price | $16.89 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 9.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.05 | $0.64 |
| 52 Week High | $20.24 | $1.81 |
| Indicator | MPV | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 40.93 |
| Support Level | $16.14 | $1.02 |
| Resistance Level | $17.33 | $1.27 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 72.11 | 16.89 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.